【摘要】：目的:探討液體活檢外周血清miR-22和miR-126的表達(dá)在非小細(xì)胞肺癌(NSCLC)發(fā)生和轉(zhuǎn)移中的作用。方法:收集鹽城市第六人民醫(yī)院2013年5月至2015年5月期間確診的127例NSCLC患者,設(shè)健康對照112例,采用q PCR檢測患者血清中miR-22和miR-126的相對表達(dá)水平,Logistic回歸分析法及ROC曲線分析miR-22和miR-126在NSCLC發(fā)展與轉(zhuǎn)移預(yù)測中的敏感性及特異性。結(jié)果:病例組血清miR-22水平顯著高于對照組,而血清miR-126水平低于對照組(均P0.05);與腺癌患者相比,鱗狀細(xì)胞癌患者的血清miR-22水平顯著升高(P0.05)、血清miR-126顯著降低(P0.01);與Ⅰ+Ⅱ期患者相比,Ⅲ+Ⅳ期患者血清miR-22水平升高、miR-126水平相對降低(均P0.01);與未轉(zhuǎn)移患者相比,轉(zhuǎn)移患者血清miR-22水平升高,而血清miR-126水平降低(均P0.01);有家族遺傳史的患者與沒有家族遺傳史的患者相比,血清miR-22水平升高但miR-126水平降低(均P0.01)。血清miR-22與miR-126水平對NSCLC預(yù)測的特異性與敏感性分別為99.11%和84.30%、82.68%和96.40%。血清miR-22與miR-126水平對NSCLC轉(zhuǎn)移的特異性與敏感性分別為59.74%和96.00%、84.00%和62.30%。結(jié)論:在NSCLC患者血清中,miR-22呈高表達(dá)而miR-26呈低表達(dá),液體活檢miR-22和miR-126可作為預(yù)測NSCLC的發(fā)生及轉(zhuǎn)移的一個生物學(xué)指標(biāo)。
[Abstract]:Aim: to investigate the role of miR-22 and miR-126 in the pathogenesis and metastasis of non-small cell lung cancer (NSCLC). Methods: 127 patients with NSCLC were collected from the sixth people's Hospital of Yancheng from May 2013 to May 2015. The relative expression level of miR-22 and miR-126 in serum was detected by qPCR and the sensitivity and specificity of miR-22 and miR-126 in the prediction of NSCLC development and metastasis were analyzed by logistic regression analysis and ROC curve analysis. Results: the serum miR-22 level in the case group was significantly higher than that in the control group, while the serum miR-126 level was lower than that in the control group (P0.05), the serum miR-22 level in squamous cell carcinoma patients was significantly higher than that in adenocarcinoma patients (P0.05), the serum miR-126 level was significantly lower (P0.01), and the level of miR-126 in patients with stage 鈪，

本文編號：2127589